ClinicalTrials.gg

Program

Cyclosporine

Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.

Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.

Furthest: phase 4, since Sep 6, 200581 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis220 open or runningphase 4since Sep 6, 2005Sep 6, 2005none ahead
Pfizer80 open or runningphase 4since Sep 13, 2005Jun 30, 2004none ahead
Hoffmann-La Roche70 open or runningphase 4since Jun 30, 2005Jun 30, 2005none ahead
Santen Pharmaceutical50 open or runningphase 3since May 19, 2006May 19, 2006none ahead
AbbVie40 open or runningphase 4since Apr 22, 2014Apr 17, 2009none ahead
Zambon SpA40 open or runningphase 3since Aug 30, 2018Aug 30, 2018none ahead
Sirion Therapeutics30 open or runningphase 3since Jul 13, 2007Jul 13, 2007none ahead
amsterdam-molecular-therapeutics20 open or runningphase 3since Apr 30, 2009Apr 30, 2009none ahead
apt-pharmaceuticals-inc20 open or runningphase 3since Sep 17, 2008Sep 17, 2008none ahead
Hanlim Pharm.20 open or runningphase 3since Dec 10, 2012Dec 10, 2012none ahead
Innovative Medical20 open or runningphase 4since Jul 5, 2006Jul 5, 2006none ahead
Novaliq20 open or runningphase 4since Mar 19, 2024Nov 25, 2015none ahead
perle-bioscience-inc20 open or runningphase 3since Jan 2, 2013Jan 2, 2013none ahead
Research Insight20 open or runningphase 4since Apr 6, 2020Apr 6, 2020none ahead
sigmoid-pharma20 open or runningphase 2since Dec 15, 2009Dec 15, 2009none ahead
Sun Pharmaceutical Industries20 open or runningphase 4since Apr 8, 2020Feb 13, 2016none ahead
fovea-pharmaceuticals-sa10 open or runningphase 2since Apr 29, 2010Apr 29, 2010none ahead
isdin10 open or runningphase 2since Dec 20, 2007Dec 20, 2007none ahead
LEO Pharma10 open or runningphase 4since Oct 16, 2018Oct 16, 2018none ahead
pari-pharma-gmbh10 open or runningphase 3since Apr 11, 2011Apr 11, 2011none ahead
perioc-limited10 open or runningphase 2since Feb 12, 2015Feb 12, 2015none ahead
Pharming Group10 open or runningphase 1since Sep 11, 2012Sep 11, 2012none ahead
spherium-biomed10 open or runningphase 2since Aug 4, 2016Aug 4, 2016none ahead
sublimity-therapeutics-holdco-limited10 open or runningphase 2since Jan 31, 2019Jan 31, 2019none ahead
Takeda10 open or runningphase 3since Nov 1, 1999Nov 1, 1999none ahead
zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd11 open or runningphase 3since Jan 3, 2025Jan 3, 2025none ahead

Also a collaborator on its studies: parexel, Dr. Falk Pharma, syreon-corporation and the-clinical-trial-company.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jan 8, 2007.

  1. Nov 4, 2016Phase 2 study in Anemia, AplasticNovartis · NCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
  2. Aug 30, 2018Zambon SpA's first studies: 2 phase 3 studies in Bronchiolitis ObliteransNew to Zambon SpAZambon SpA · NCT03657342, NCT03656926
  3. Oct 16, 2018LEO Pharma's first study: phase 4 study in Dermatitis, AtopicNew to LEO PharmaLEO Pharma · NCT03710044 · Netherlands
  4. Jan 31, 2019sublimity-therapeutics-holdco-limited's first study: phase 2 study in Colitis, UlcerativeNew to sublimity-therapeutics-holdco-limitedsublimity-therapeutics-holdco-limited · NCT03844932 · 235 enrolled · United States, Belarus, Bulgaria and more
  5. Jul 19, 2019Phase 3 study in Bronchiolitis ObliteransZambon SpA · NCT04039347 · 164 enrolled · United States, Austria, Belgium and more
  6. Sep 25, 2019Phase 2 study in Bronchiolitis Obliterans SyndromeZambon SpA · NCT04107675 · 6 enrolled · France, Germany, Spain
  7. Oct 25, 2019Phase 3 study in Dry Eye Disease With Severe KeratitisSanten Pharmaceutical · NCT04144413 · 350 enrolled · Czechia, France, Italy and more
  8. Mar 9, 2020Phase 2 study in Anemia, AplasticNovartis · NCT04328727 · 36 enrolled · China, Japan, South Korea and more
  9. Apr 6, 2020Research Insight's first study: phase 4 study in Dry Eye SyndromesNew to Research InsightResearch Insight · NCT04342988 · 74 enrolled · United States
  10. Apr 8, 2020Phase 4 study in Dry Eye SyndromesSun Pharmaceutical Industries · NCT04357795 · 135 enrolled · United States
  11. Mar 19, 2024Phase 4 study in Dry Eye SyndromesNovaliq · NCT06329661 · 204 enrolled · United States
  12. Jun 25, 2024Phase 4 study in Dry Eye SyndromesResearch Insight · NCT06482177 · 52 enrolled · United States
  13. Jan 3, 2025zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd's first study: phase 3 study in Moderate to Severe Dry EyeNew to zhaoke-guangzhou-ophthalmology-pharmaceutical-ltdzhaoke-guangzhou-ophthalmology-pharmaceutical-ltd · NCT06766357 · 360 planned · China
  14. Jun 16, 2025Phase 4 study in Dry Eye SyndromesHoffmann-La Roche · NCT07025811 · 378 enrolled · United States

TargetBeta

PPIA →read by rule
“Cyclophilin A modulator”ChEMBL 37, by rule

Studies

The newest 60 of 81 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07025811Dry Eye Syndromes · United States4CompletedHoffmann-La RocheJul 16, 2026378
NCT06766357Moderate to Severe Dry Eye · China3Recruitingzhaoke-guangzhou-ophthalmology-pharmaceutical-ltdFeb 2026360
NCT06482177Dry Eye Syndromes · United States4CompletedResearch InsightJun 5, 202452
NCT06329661Dry Eye Syndromes · United States4CompletedNovaliqJul 30, 2025204
NCT04357795Dry Eye Syndromes · United States4CompletedSun Pharmaceutical IndustriesJun 24, 2022135
NCT04342988Dry Eye Syndromes · United States4CompletedResearch InsightDec 31, 202074
NCT04328727Anemia, Aplastic · China, Japan, South Korea and more2CompletedNovartisJun 10, 202236
NCT04144413Dry Eye Disease With Severe Keratitis · Czechia, France, Italy and more3CompletedSanten PharmaceuticalJul 14, 2023350
NCT04107675Bronchiolitis Obliterans Syndrome · France, Germany, Spain2TerminatedZambon SpAJun 16, 20226
NCT04039347Bronchiolitis Obliterans · United States, Austria, Belgium and more3TerminatedZambon SpAFeb 25, 2026164
NCT03844932Colitis, Ulcerative · United States, Belarus, Bulgaria and more2Terminatedsublimity-therapeutics-holdco-limitedApr 14, 2021235
NCT03710044Dermatitis, Atopic · Netherlands4WithdrawnLEO PharmaAug 20200
NCT03657342Bronchiolitis Obliterans · United States, Belgium, France and more3CompletedZambon SpAApr 16, 202462
NCT03656926Bronchiolitis Obliterans · United States, Austria, Belgium and more3CompletedZambon SpAMar 12, 2024169
NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more2CompletedNovartisNov 3, 202054
NCT02865356Dermatitis, Atopic · Spain2Completedspherium-biomedApr 12, 201736
NCT02688556Keratoconjunctivitis Sicca · United States3CompletedSun Pharmaceutical IndustriesNov 2016745
NCT02630563Pediatric Liver Transplantation · United States2TerminatedHoffmann-La RocheJan 20059
NCT02617667Dry Eye Syndromes · United States2CompletedNovaliqJul 2016207
NCT02554981Dry Eye Syndromes · United States4CompletedAbbVieMar 24, 201651
NCT02404025Anemia, Aplastic · Japan2CompletedNovartisJul 5, 201610
NCT02366585Periodontitis · Sweden2Completedperioc-limitedSep 201623
NCT02229955Dry Eye Syndromes · Korea, Republic of3CompletedHanlim Pharm.Apr 201486
NCT02130414Healthy1Completedsigmoid-pharmaJan 201548
NCT02121847Dry Eye Syndromes · United States4CompletedAbbVieSep 23, 201440
NCT02091414Heart Transplantation · China3CompletedHoffmann-La RocheFeb 200936
NCT02005562Kidney Transplantation · France3CompletedHoffmann-La RocheMar 2009252
NCT01843348Rejection, Psychology · France, Germany3CompletedNovartisMar 23, 2016612
NCT01762657Diabetes Mellitus, Type 13Withdrawnperle-bioscience-incSep 20150
NCT01762644Diabetes Mellitus, Type 13Withdrawnperle-bioscience-incMay 20160
NCT01751126Conjunctivitis, Allergic · United States, Croatia, France and more3CompletedSanten PharmaceuticalFeb 2016169
NCT01768312Dry Eye Syndromes · Korea, Republic of3CompletedHanlim Pharm.Jul 31, 201384
NCT01692834Healthy · South Africa1CompletedPharming GroupJan 201065
NCT01601821Inflammation · Iran, Islamic Republic of4CompletedPfizerMar 2008245
NCT01552629Dermatitis, Atopic · Austria, France, Germany2CompletedNovartisAug 28, 201322
NCT01514968Healthy Volunteer · United States1CompletedHoffmann-La RocheFeb 201218
NCT01596062Renal Transplantation · France2CompletedNovartisMar 201316
NCT01334892Bronchiolitis Obliterans · Germany3Terminatedpari-pharma-gmbhJul 2013130
NCT01276457Transplantation Infection3CompletedNovartisFeb 2009223
NCT01120132Conjunctivitis, Allergic · United States2Completedfovea-pharmaceuticals-saAug 2010716
NCT01109498Hyperlipoproteinemia Type I · Canada3UNKNOWNamsterdam-molecular-therapeuticsJun 201314
NCT01033305Mild to Moderate Ulcerative Colitis · Ireland, United Kingdom2Completedsigmoid-pharmaAug 2011118
NCT00991458Laser In Situ Keratomileusis · United States2CompletedAbbVieApr 2011621
NCT00938860Hepatitis C · United States, Belgium, Brazil and more4CompletedNovartisMay 201392
NCT00938236Bronchiolitis Obliterans Syndrome · United States, Canada3Terminatedapt-pharmaceuticals-incSep 201117
NCT00891306Hyperlipoproteinemia Type I · Canada3Completedamsterdam-molecular-therapeuticsAug 20105
NCT00884585Conjunctivitis, Allergic · United States, Australia, Canada and more3CompletedAbbVieOct 2010176
NCT00814515Lymphoma, Follicular · France3CompletedSanten PharmaceuticalSep 2009482
NCT00755781Bronchiolitis Obliterans Syndrome · United States, Canada3Completedapt-pharmaceuticals-incSep 2011284
NCT00739349Dry Eye Syndromes · United States2CompletedSanten PharmaceuticalJan 2009132
NCT00578370Psoriasis · Germany2CompletedisdinApr 200825
NCT00549289Dry Eye Syndromes · United States3CompletedSirion Therapeutics
NCT00548301Dry Eye Syndromes · United States3CompletedSirion Therapeutics
NCT00518375Kidney Transplantation4CompletedPfizer250
NCT00507793Kidney Transplantation4CompletedPfizer385
NCT00504543Kidney Transplantation · Argentina, Australia, Austria and more2CompletedNovartisApr 2011311
NCT00502073Dry Eye Syndromes · United States3CompletedSirion Therapeutics
NCT00438360Chronic Plaque Psoriasis · Italy3CompletedNovartisNov 2007243
NCT00428064Renal Transplantation3CompletedPfizer408
NCT00419926Kidney Transplantation · Switzerland4CompletedNovartisJun 2009313

How it is read

Names in the registry

  • “cyclosporine”, 12 entries
  • “Cyclosporine”, 10 entries
  • “Cyclosporine A”, 6 entries
  • “Ciclosporin”, 4 entries
  • “Liposomal Cyclosporine A”, 3 entries

Codes read as this program: NOVA22007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.